文献速递眼底病与葡萄膜炎青光眼

眼科临床试验的终点指标

Endpoints for clinical trials in ophthalmology.
PubMed 文献 · Prog Retin Eye Res · 2023-01-02

随着新靶点发现,眼科介入性临床试验数量增加。长期被视为金标准的视力终点已显不足,地图样萎缩、遗传性视网膜疾病及青光眼神经保护试验均需其他终点。本文总结视网膜疾病与青光眼领域候选临床终点,涵盖功能与结构生物标志物及生活质量指标,并对其作为关键试验终点的潜力进行批判性评价。

要点

  • 视力长期被视为临床试验金标准终点,但地图样萎缩和遗传性视网膜疾病等适应症需要其他终点。
  • 青光眼现有药物基于降眼压能力获批,但近期发现同等降眼压水平下不同药物对视野进展影响可能不同。
  • 青光眼神经保护试验需要新的替代终点,可包括功能或结构参数或两者组合。

核心结论

  • 已识别出若干眼科临床试验的潜在替代终点,但其验证复杂且需要坚实的科学证据。

研究设计与样本

  • 本文为综述,聚焦视网膜疾病与青光眼,总结眼科临床试验候选终点并批判性评价其作为关键试验终点的潜力。

主要发现

  • 随着新靶点发现,眼科介入性临床试验数量增加。
  • 视力长期被视为临床试验金标准终点,但近年发现地图样萎缩和遗传性视网膜疾病等多种适应症需要其他终点。
  • 青光眼现有药物基于降眼压能力获批,但近期发现同等降眼压水平下并非所有药物对视野进展影响相同。
  • 青光眼神经保护试验需要新的替代终点,可包括功能或结构参数或两者组合。
  • 已识别出若干眼科临床试验潜在替代终点,但其验证复杂且需要坚实的科学证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With the identification of novel targets, the number of interventional clinical trials in ophthalmology has increased. Visual acuity has for a long time been considered the gold standard endpoint for clinical trials, but in the recent years it became evident that other endpoints are required for many indications including geographic atrophy and inherited retinal disease. In glaucoma the currently available drugs were approved based on their IOP lowering capacity. Some recent findings do, however, indicate that at the same level of IOP reduction, not all drugs have the same effect on visual field progression. For neuroprotection trials in glaucoma, novel surrogate endpoints are required, which may either include functional or structural parameters or a combination of both. A number of potential surrogate endpoints for ophthalmology clinical trials have been identified, but their validation is complicated and requires solid scientific evidence. In this article we summarize candidates for clinical endpoints in ophthalmology with a focus on retinal disease and glaucoma. Functional and structural biomarkers, as well as quality of life measures are discussed, and their potential to serve as endpoints in pivotal trials is critically evaluated.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Schmetterer L, Scholl H, Garhöfer G, et al. Endpoints for clinical trials in ophthalmology. Prog Retin Eye Res. 2023. PMID: 36599784. doi:10.1016/j.preteyeres.2022.101160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。